Active Ingredient History
Preladenant was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson's disease. Positive results were reported in Phase II clinical trials in humans, but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Akathisia, Drug-Induced (Phase 2)
Antipsychotic Agents (Phase 2)
Brain Diseases (Phase 2)
Central Nervous System Diseases (Phase 2)
Dyskinesia, Drug-Induced (Phase 2)
Liver Diseases (Phase 1)
Movement Disorders (Phase 2)
Neoplasms (Phase 1)
Neurodegenerative Diseases (Phase 2)
Parkinson Disease (Phase 3)
Parkinsonian Disorders (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue